Newsfeeds - Spark Newswire

1 minute read

JonesTrading Initiates Coverage On Omega Therapeutics with Buy Rating, Announces Price Target of $11

Today, 2:08 PM

JonesTrading analyst Catherine Novack initiates coverage on Omega Therapeutics (NASDAQ:OMGA) with a Buy rating and announces Price Target of $11.

OMGA

1 minute read

Piper Sandler Maintains Overweight on Omega Therapeutics, Raises Price Target to $10

By Benzinga Newsdesk

Today, 2:08 PM

Piper Sandler analyst Edward Tenthoff maintains Omega Therapeutics (NASDAQ:OMGA) with a Overweight and raises the price target from $8 to $10.

OMGA

3 minute read

Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

Today, 2:08 PM

Gainers Hempacco Co., Inc. (NASDAQ: HPCO) rose 296% to $2.99 after declining 6% on Wednesday.

AFRM

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 2:08 PM

Gainers SmileDirectClub (NASDAQ:SDC) stock increased by 47.0% to $0.71 during Monday’s regular session. SmileDirectClub’s stock is trading at…

ATIP

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 2:08 PM

Gainers Yield10 Bioscience (NASDAQ:YTEN) shares increased by 35.2% to $2.84 during Thursday’s regular session. Trading volume for Yield10…

DRTS

1 minute read

Omega Therapeutics Could Offer ‘Intriguing’ Liver Cancer Drug, Analyst Says

By Vandana Singh

Today, 2:08 PM

HC Wainwright has initiated coverage on Omega Therapeutics Inc (NASDAQ:OMGA) with a Buy rating and a price target of $11. The analyst…

OMGA

1 minute read

Omega Therapeutics Receives Orphan Drug Designation For OTX-2002 For The Treatment Of Hepatocellular Carcinoma

By Benzinga Newsdesk

Today, 2:08 PM

Omega Therapeutics, Inc. ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines, today announced

OMGA

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 23, 2022

By Benzinga Insights

Today, 2:08 PM

Upgrades

ALLY

1 minute read

Chardan Capital Initiates Coverage On Omega Therapeutics with Buy Rating, Announces Price Target of $12

By Benzinga Newsdesk

Today, 2:08 PM

Chardan Capital analyst Keay Nakae initiates coverage on Omega Therapeutics (NASDAQ:OMGA) with a Buy rating and announces Price Target of $12.

OMGA

2 minute read

Earnings

Omega Therapeutics Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 2:08 PM

Benzinga Pro data, Omega Therapeutics (NASDAQ:OMGA) reported Q2 sales of $476 thousand. Earnings fell to a loss of $25.91 million, resulting in a 28.51% decrease from last quarter.

OMGA